Partnering with Bigpharma: The definitive guide to partnering interests, contacts & agreements

Abstract

The Partnering with Bigpharma: The Definitive Guide to Bigpharma Partnering Interests, Contacts and Agreements report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies. This premier report provides all the information you require to better understand bigpharma partnering.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company' s business development objectives. Over 200 charts allow quick understanding of each bigpharma companies dealmaking trends over the last four years.

This report contains over 1,200 links to online copies of actual contract documents as submitted to the Securities Exchange Commission by bigpharma and their partners.

Contract documents provide the answers to numerous questions about a prospective partner' s flexibility on a wide range of important issues, many of which will have a significant impact on each party' s ability to derive value from the deal.

The initial Chapters of this report provide an orientation of bigpharma' s dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst Chapter 2 lists the top 50 leading biopharma companies based on 2006 pharmaceutical revenues and dealmaking activity since 2005.

Chapter 3 analyzes the most active dealmakers since 2005 in M&A and partnering deals announced, whilst Chapter 4 analyzes the top deals of 2005-8 according to reported deal size.

Chapter 5 provides a summary on best practice on how to submit an opportunity to bigpharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

Chapter 6 lists forthcoming partnering events where valuable face to face meetings with bigpharma provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.

The main body of the report is provided in Chapter 7 and 8.

Firstly, a series of matrices provide a cross reference for each bigpharma company versus therapy area with respect to marketed and pipeline activity, partnering interests, and partnering activity in the last two years.

Secondly, in-depth profiles of every bigpharma company provide everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company' s marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. Each profile also includes in-depth contact information for individuals within the business development function.

• Detailed company profiles for each of the top 50 bigpharma companies
• Over 200 charts showing a company' s dealmaking activity since 2005, allowing quick identification potential partners
• In-depth marketed and pipeline product activity of each company
• Partnering interests and therapy focus revealed
• Partnering activity since 2000 - number of deals per year
• Partnering activity for 2005-2008
  • Activity by deal type
  • Activity by phase of development
  • Activity by therapeutic area
  • List of recent partner companies
• Comprehensive access to over 1,200 actual contracts entered into by the leading fifty biopharma companies*
• Insight into the terms included in a partnering agreement, together with real world clause examples
• Understand the key deal terms the company has agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

*Subject to being published via regulatory requirements of the Securities Exchange Commission.

Partnering with Bigpharma is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the leading fifty biopharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company' s approach to partnering.

• Detailed company profiles for each of the top 50 bigpharma companies, including:
  • Full contact details
  • Business developer contact details including name, title, email and telephone (where available)
  • Marketed indications
  • Pipeline indications
  • Partnering interests and indications
  • Partnering activity since 2000
  • Current partner companies since 2005
  • Partnering activity since 2005 by:
    • Deal type
    • Stage of development
    • Therapy area
• Over 200 charts showing the dealmaking activity of each company since 2005
• The tools to enable effective and efficient preparation for partnering negotiation with bigpharma
• Listing of over 1,200 contract documents between bigpharma and partner companies
• The leading M&A and partnering deals by value 2005-8
• Most active M&A and partnering dealmakers 2005-8

The Partnering with Bigpharma report also provides comprehensive access to available contract documents for each of the fifty bigpharma companies.

• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subscontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

For each company in Partnering with Bigpharma report, the available contracts are listed by deal type, including:

• Co-development
• Co-marketing
• Co-promotion
• Collaborative R&D
• Development
• Distribution
• Joint venture
• Licensing
• M&A
• Manufacturing
• Marketing
• Promotion
• Research
• Supply

Number of pages:

The report is comprised of 648 pages.